Vestcor Inc’s TG Therapeutics TGTX Stock Holding History

Vestcor Inc’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-83	Closed	-$1K	–	1304
2023 Q3	$1K	Sell	83 -22,755	-100%	-$317K	﹤0.01%	1282
2023 Q2	$567K	Buy	+22,838	New	+$590K	0.02%	579

Other funds holding TGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Vestcor Inc's TGTX Position: Q4 2023 in Review

Vestcor Inc sold out of TG Therapeutics (TGTX) in Q4 2023, closing a stake of 83 shares — an estimated $1K sold.

Vestcor Inc first reported a position in TGTX in Q2 2023 and held it in 2 quarters. The position peaked at $567K in Q2 2023. 235 funds tracked by Wall St. Rank hold TGTX as of Q4 2023.

Vestcor Inc reported no remaining TG Therapeutics position as of Q4 2023 after selling out during the quarter.
Vestcor Inc sold 83 TG Therapeutics shares in Q4 2023, an estimated $1K.
Vestcor Inc first reported a position in TG Therapeutics in Q2 2023 and held it in 2 quarters.
Vestcor Inc's TG Therapeutics position peaked at $567K in Q2 2023.
235 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2023.

Based on Vestcor Inc's 13F filing for Q4 2023, filed 14 Feb 2024.